BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24610083)

  • 1. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs.
    Oskarsson A; Spatafora C; Tringali C; Andersson ÅO
    Prostate; 2014 Jun; 74(8):839-51. PubMed ID: 24610083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor.
    Lundqvist J; Tringali C; Oskarsson A
    J Steroid Biochem Mol Biol; 2017 Nov; 174():161-168. PubMed ID: 28888979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
    Lin CJ; Cheng LC; Lin TC; Wang CJ; Li LA
    Biochem Pharmacol; 2014 Aug; 90(3):288-96. PubMed ID: 24875446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
    de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
    J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
    Krug SJ; Hu Q; Hartmann RW
    J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities.
    Marti N; Bouchoucha N; Sauter KS; Flück CE
    PLoS One; 2017; 12(3):e0174224. PubMed ID: 28323907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressed Sex Hormone Biosynthesis by Alkylresorcinols: A Possible Link to Chemoprevention.
    Oskarsson A; Ohlsson Andersson Å
    Nutr Cancer; 2016; 68(6):978-87. PubMed ID: 27352233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetaminophen Increases Aldosterone Secretion While Suppressing Cortisol and Androgens: A Possible Link to Increased Risk of Hypertension.
    Oskarsson A; Ullerås E; Ohlsson Andersson Å
    Am J Hypertens; 2016 Oct; 29(10):1158-64. PubMed ID: 27217499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of resveratrol analogs on steroidogenesis and mitochondrial function in rat Leydig cells in vitro.
    Svechnikov K; Spatafora C; Svechnikova I; Tringali C; Söder O
    J Appl Toxicol; 2009 Nov; 29(8):673-80. PubMed ID: 19603415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
    Kosaka T; Miyajima A; Yasumizu Y; Miyazaki Y; Kikuchi E; Oya M
    Steroids; 2014 Dec; 92():39-44. PubMed ID: 25150014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of methoxychlor and its metabolite 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on human and rat 17α-hydroxylase/17,20-lyase activity.
    Ye L; Chen X; Li X; Zhu Q; Yu L; Guo J; Chen B; Akingbemi BT; Ge RS; Li H
    Toxicol Lett; 2014 Mar; 225(3):407-12. PubMed ID: 24451217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of differential P450c17 phosphorylation by cAMP stimulation and by starvation conditions on enzyme activities and androgen production in NCI-H295R cells.
    Kempná P; Hirsch A; Hofer G; Mullis PE; Flück CE
    Endocrinology; 2010 Aug; 151(8):3686-96. PubMed ID: 20534731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C-induced activin A switches adrenocortical steroidogenesis to aldosterone by suppressing CYP17A1 expression.
    Hofland J; Steenbergen J; Hofland LJ; van Koetsveld PM; Eijken M; van Nederveen FH; Kazemier G; de Herder WW; Feelders RA; de Jong FH
    Am J Physiol Endocrinol Metab; 2013 Sep; 305(6):E736-44. PubMed ID: 23900415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
    Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition.
    Kmeťová Sivoňová M; Jurečeková J; Tatarková Z; Kaplán P; Lichardusová L; Hatok J
    Gen Physiol Biophys; 2017 Dec; 36(5):487-499. PubMed ID: 29372682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha regulates steroidogenesis, apoptosis, and cell viability in the human adrenocortical cell line NCI-H295R.
    Mikhaylova IV; Kuulasmaa T; Jääskeläinen J; Voutilainen R
    Endocrinology; 2007 Jan; 148(1):386-92. PubMed ID: 17038555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
    Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
    Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro effects of brominated flame retardants and metabolites on CYP17 catalytic activity: a novel mechanism of action?
    Cantón RF; Sanderson JT; Nijmeijer S; Bergman A; Letcher RJ; van den Berg M
    Toxicol Appl Pharmacol; 2006 Oct; 216(2):274-81. PubMed ID: 16828825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.